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From basics to clinic: Cancer 
Nanotechnology
Fred Currell1*, Steven Curley2, Željka Krpetić3 and Mark Bellringer4*
Cancer is a group of diseases driven by inherently nanostructural problems (e.g. DNA 
issues). As such, there are obvious benefits to treatments employing nanoscale struc-
tures and processes. Additionally, as nanotechnologies are developing at a rapid rate, it is 
likely that many new themes will develop within the area in the next few years. With this 
in mind, Cancer Nanotechnology aims to provide a forum so that the most promising 
emerging themes should be pre-eminent in the minds of researchers working in one—or, 
indeed, both—of the disciplines of cancer research or nanotechnology.
Cancer Nanotechnology is published by SpringerOpen, a suite of fully open access 
journals that is part of the wider Springer Nature group. It enjoys a growing readership 
with an ever-increasing number of papers receiving double-digit citations.
As we near the end of another year in the life of Cancer Nanotechnology, it is worth 
reflecting upon the journal’s raison d’être and future direction.
The label is very much on the tin! Cancer Nanotechnology concerns itself with all that 
is new at the intersection of cancer research and nanotechnology. Relationships to can-
cer are deliberately interpreted broadly, encompassing: prevention, treatment, diagnosis, 
and related regulatory frameworks. Nanotechnology is taken to mean anything involv-
ing objects with characteristic length scales typically below 500  nm, but also includes 
the induction of nanoscale processes, for example by the injection of energy or various 
substances.
These definitions are intentionally wide, and the journal continues this approach: sub-
missions accepted range from fundamental discovery and creation of basic techniques—
including all phases of development—to the clinical application of nano-processes and 
technologies in relation to cancer treatment, diagnosis, and prevention.
One distinctive feature of the journal is the hosting of special thematic article collec-
tions; each collection serves to illustrate a research area’s present status and/or to high-
light cutting-edge developments.
Such a collection acts as a vehicle which the research community can use to make 
important connections explicit and more widely disseminated. Furthermore, a collec-
tion comprising mainly review articles has the scope to show historical trend, whilst one 
focusing on original research can capture disruptive change. Of course, a collection can 
contain a mix of original research and reviews, offering the opportunity to trace both 
historical trend and innovative discontinuity. If there is a substantive development at the 
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intersection of cancer and nanotechnology, then it needs a special thematic article col-
lection—the journal’s editorial team welcomes your suggestions in this regard.
What is more, a key feature of collections is that they are ever evolving. As an online-
only publication, Cancer Nanotechnology is not constrained by the rules of traditional 
special issues, the print analogy to our special collections. This allows the special col-
lections to be dynamic—they can be updated as new, relevant, research is reported even 
several years after the first papers comprising the collection came together.
It is possible that any of the papers found in Cancer Nanotechnology could well have 
found an alternative venue for publication. But it would be much harder to find another 
specialist journal featuring the full diversity of this subject area. The intention is to cre-
ate a unified forum for the full gamut of relevant research, thereby allowing develop-
ments and connections across the field to become apparent. We invite you to join us on 
our journey towards making this a reality.
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